Amylyx Pharmaceuticals Inc (AMLX)
3.65 +0.16 (+4.58%) 04/11/25 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime 3.67 +0.02 (+0.55%) 19:42 ET
for Fri, Apr 11th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
Cash Flows From Operating Activities | |||||
Net Income | -301,743 | 49,271 | -198,375 | -87,931 | -42,280 |
Depreciation Amortization | -8,952 | -8,852 | -1,569 | 173 | 1 |
Accounts receivable | 39,602 | -24,744 | -15,306 | N/A | N/A |
Accounts payable and accrued liabilities | -19,102 | 15,882 | 1,854 | 670 | 1,418 |
Other Working Capital | -45,831 | -65,661 | -1,641 | 4,595 | 2,599 |
Other Operating Activity | 168,379 | 46,023 | 35,166 | 7,694 | 1,565 |
Operating Cash Flow | $-167,647 | $11,919 | $-179,871 | $-74,799 | $-36,697 |
Cash Flows From Investing Activities | |||||
Change In Deposits | 112,014 | 93,294 | -236,462 | -46,053 | N/A |
PPE Investments | -36,360 | -1,241 | -2,526 | -353 | -151 |
Investing Cash Flow | $75,654 | $92,053 | $-238,988 | $-46,406 | $-151 |
Cash Flows From Financing Activities | |||||
Debt Issued | N/A | N/A | N/A | 26,159 | 16,554 |
Debt Repayment | N/A | N/A | N/A | -263 | 263 |
Common Stock Issued | 2,132 | 6,858 | 434,636 | 343 | 48 |
Other Financing Activity | -1,784 | -3,315 | -2,847 | 132,267 | 29,958 |
Financing Cash Flow | $348 | $3,543 | $431,789 | $158,506 | $46,823 |
Exchange Rate Effect | -438 | 160 | -65 | 13 | N/A |
Beginning Cash Position | 170,920 | 63,245 | 50,380 | 13,066 | 3,091 |
End Cash Position | 78,837 | 170,920 | 63,245 | 50,380 | 13,066 |
Net Cash Flow | $-92,083 | $107,675 | $12,865 | $37,314 | $9,975 |
Free Cash Flow | |||||
Operating Cash Flow | -167,647 | 11,919 | -179,871 | -74,799 | -36,697 |
Capital Expenditure | -36,360 | -1,241 | -2,526 | -353 | -151 |
Free Cash Flow | -204,007 | 10,678 | -182,397 | -75,152 | -36,848 |